DISEASE INDICATIONS: Psoriasis

MANUFACTURER: Almirall, S.A.

USAGE: Subcutaneous

MEDICINE APPROVED BY:

European Medical Agency (EMA)

Food and Drug Administration (FDA)

Ilumya (tildrakizumab) is a prescription medication that treats moderate to severe plaque psoriasis in adults by selectively targeting IL-23 to reduce inflammation and skin cell proliferation.